Strength Seen in Alkermes (ALKS): Stock Soars 8.7%
Alkermes plc ALKS was a big mover last session, as the company saw its shares rise more than 8% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $53.61 to $59.85 in the past one-month time frame.
The company has seen three positive estimate revisions in the past one month, while the Zacks Consensus Estimate has also moved higher over the said time period, suggesting that more solid trading could be ahead for Alkermes. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Alkermes currently has a Zacks Rank #2 (Buy), while its Earnings ESP is positive.
Alkermes PLC Price
Alkermes PLC Price | Alkermes PLC Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Exelixis, Inc. EXEL, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ALKS going up? Or down? Predict to see what others think: Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes PLC (ALKS) : Free Stock Analysis Report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
